Focus in Ovarian Cancer

Morgan Bailey,Susan Morand,Rachel Royfman,Leslie Lin,Aditi Singh,Laura Stanbery,Adam Walter,Danae Hamouda,John Nemunaitis

DOI: https://doi.org/10.3390/ijms25063173

IF: 5.6

2024-03-10

International Journal of Molecular Sciences

Abstract:The emergence of targeted therapeutics in ovarian cancer, particularly poly (ADP-ribose) polymerase inhibitors (PARPi's), has created additional opportunities for patients seeking frontline and recurrent disease management options. In particular, PARPi's have shown clinical benefits in BRCA mutant and/or homologous recombination deficient (HRD) ovarian cancer. Until recently, response was thought to be limited in BRCA wild-type, homologous recombination proficient (HRP) cancers. Therefore, attempts have been made at combination therapy involving PARPi to improve patient outcomes. Additionally, immune checkpoint inhibitors (ICIs) have demonstrated underwhelming results involving ovarian cancer. Many are searching for reliable biomarkers of immune response to increase efficacy of ICI therapy involving ovarian cancer. In this review, we examine the evidence supporting the combination of PARPi and ICIs in ovarian cancer, which is still lacking.

biochemistry & molecular biology,chemistry, multidisciplinary

What problem does this paper attempt to address?

The paper primarily explores the combined application of Poly (ADP-ribose) polymerase inhibitors (PARP inhibitors) and immune checkpoint inhibitors (ICI) in the treatment of ovarian cancer. Specifically, the paper focuses on the following aspects:

1. **Background and Objectives**: PARP inhibitors have shown clinical benefits in ovarian cancer patients with BRCA mutations or homologous recombination deficiency (HRD), while immune checkpoint inhibitors have not been very effective in ovarian cancer treatment. Researchers attempt to improve patient outcomes by combining these two therapies.

2. **Mechanism of Action of PARP Inhibitors**: PARP proteins are involved in the DNA repair process. PARP inhibitors disrupt the DNA repair mechanism of cancer cells by inhibiting these proteins, leading to cancer cell death.

3. **Clinical Evidence of PARP Inhibitors in Ovarian Cancer**: The paper reviews the clinical trial results of several PARP inhibitors (such as olaparib, niraparib, and rucaparib) approved for ovarian cancer treatment. It points out that although these drugs show significant efficacy in specific subgroups (such as patients with BRCA mutations or HRD-positive), their impact on overall survival (OS) in late-stage patients after multiple lines of standard chemotherapy is controversial.

4. **Relationship Between Immune Activity and PARP Inhibitors**: PARP inhibitors can enhance immune activity in the tumor microenvironment by activating pathways such as cGAS/STING. Theoretically, this could increase the effectiveness of immune checkpoint inhibitors. However, PARP inhibitors may also inhibit immune response by upregulating PD-L1 expression, thereby reducing the efficacy of ICIs.

5. **Current Status of Combined Treatment with PARP Inhibitors and Immune Checkpoint Inhibitors**: Although there is a theoretical basis to believe that the combination of PARP inhibitors and ICIs can have a synergistic effect, current clinical trials have not provided sufficient evidence to support the significant benefits of this combined therapy in ovarian cancer treatment. The paper emphasizes the need for further research to determine the best patient selection strategies and biomarker-guided treatment plans.

In summary, the paper aims to evaluate whether the combined application of PARP inhibitors and immune checkpoint inhibitors in ovarian cancer treatment has clinical benefits. It also explores the biological mechanisms behind this combined therapy and the current challenges faced.